Ageing: it’s an inevitable part of life, it affects us all, and there’s just no way around it.
Or is there? “Ageing is a major societal problem that we’re turning our attention to in the biotechnology industry as something that’s treatable…
and that we can modify biologically to improve the health span of people in our country and worldwide,” says Dr. Joshua Hare, co-founder, and chief science officer at Longeveron. Founded four years ago after receiving a technology license from the University of Miami Interdisciplinary Stem Cell Institute, Longeveron is a biotech company bringing over 20 years of clinical research and 40 years of basic research to address the problem of ageing.
The team at Longeveron proposes that allogeneic mesenchymal stem cells can be used to treat ageing frailty, a condition that affects 50 percent of people over the age of 65. Dr. Hare discusses the evidence in support of his hypothesis, the regenerative and reparative potential of these stem cells, how to determine the best method of delivery, why ageing frailty is a condition that’s particularly likely to respond positively to these types of stem cells, roadblocks to the development of research in this field, and what he thinks will happen over the next few years.
Tune in for the full conversation, and visit longeveron.com to learn more.